Targeted Molecular Therapeutics for Bladder Cancer—A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?

The fact that there are now five immune checkpoint inhibitor (ICI) monoclonal antibodies approved since 2016 that target programmed cell death protein 1 or programmed death ligand-1 for the treatment of metastatic and refractory bladder cancer is an outstanding achievement. Although patients can dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bednova, Olga, Leyton, Jeffrey V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582582/
https://www.ncbi.nlm.nih.gov/pubmed/33019653
http://dx.doi.org/10.3390/ijms21197268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7582582/
https://www.ncbi.nlm.nih.gov/pubmed/33019653
http://dx.doi.org/10.3390/ijms21197268

Ejemplares similares